AbbVie, Simcere Zaiming

AbbVie and Simcere Zaiming link to develop trispecific antibody
The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.
AbbVie, Simcere Zaiming announce partnership to develop SIM0500
AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500,
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory
AbbVie, Simcere Zaiming Partner to Develop Trispecific Antibody in Multiple Myeloma
AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., entered an option to license agreement to develop SIM0500, an investigational new drug candidate in Phase 1 trials in relapsed or refractory multiple myeloma (MM), in both China and the U.S.
AbbVie And Simcere Zaiming Partner To Develop Innovative Cancer Drug SIM0500
AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement
AbbVie keeps adding cancer treatments with $1B licensing deal for new drug
In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in a deal worth more than $1 billion.
AbbVie secures option to license Simcere's blood cancer drug candidate
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer drug candidate outside China.
PMLiVE10h
AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn
AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...
FierceBiotech2d
JPM25: AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager
Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...
BioWorld2d
Abbvie and Simcere enter a $1B T-cell engager deal
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug ...